Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 2/20 | 0.45 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.44 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.44 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.44 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.44 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.44 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.44 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25605312 | 0.82 | PRKAB2 (0.43) | SMN1; SMN2NPC1RAB9ANR3C1PARP1 | |
| SCHEMBL25790406 | 0.81 | GPR119 (0.40) | NR3C1PARP1PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL178410 | 0.80 | CNR1 (0.52) | SMN1; SMN2NPC1RAB9ANR3C1PRKAB2 | |
| SCHEMBL12794020 | 0.79 | NPC1 (0.51) | SMN1; SMN2NPC1RAB9ALMNAMAPT | |
| SCHEMBL22387208 | 0.79 | NPC1 (0.51) | SMN1; SMN2NPC1RAB9ALMNAMAPT | |
| SCHEMBL25692506 | 0.78 | SMYD3 (0.55) | SMN1; SMN2NPC1RAB9ATSHRBRD4 | |
| SCHEMBL17253106 | 0.78 | PRKAB2 (0.48) | NPC1RAB9APRKAB2PRKAG1PRKAA2 | |
| SCHEMBL16472325 | 0.78 | CHRM2 (0.55) | SMN1; SMN2NPC1RAB9ALMNAMAPT | |
| SCHEMBL20046069 | 0.78 | AR (0.65) | PRKAA2 | |
| SCHEMBL24833741 | 0.77 | CRBN (0.62) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802128-B2 | Azetidine and pyrrolidine PARP1 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| WO-2023134647-A1 | PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 优领医药科技(香港)有限公司 | 2023-07-20 | — | — | WO | disclosed |
| US-20230203033-A1 | AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023109521-A1 | PARP INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | 凯复(苏州)生物医药有限公司 | 2023-06-22 | — | — | WO | disclosed |
| US-20230128041-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230128041-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-04-27 | — | — | US | disclosed |
| US-11591331-B2 | PARP1 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-10308652-B2 | Tricyclic heterocyclic compounds useful as inhibitors of TNF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180111937-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TNF | BRISTOL MYERS SQUIBB CO (US) | 2018-04-26 | — | — | US | disclosed |
| US-8987268-B2 | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-24 | — | — | US | disclosed |
| US-8962637-B2 | Bicyclic compounds and their uses as dual c-SRC/JAK inhibitors | DEBIOPHARM S.A. (CH) | 2015-02-24 | — | — | US | disclosed |
| US-8962637-B2 | Bicyclic compounds and their uses as dual c-SRC/JAK inhibitors | DEBIOPHARM S.A. (CH) | 2015-02-24 | — | — | US | disclosed |
| EP-2536722-B1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | DEBIOPHARM SA (CH) | 2014-04-16 | — | — | EP | disclosed |
| US-20140011800-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-09 | — | — | US | disclosed |
| US-20130143895-A1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | DEBIOPHARM S.A. (CH) | 2013-06-06 | — | — | US | disclosed |
| US-20130143895-A1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | DEBIOPHARM S.A. (CH) | 2013-06-06 | — | — | US | disclosed |
| US-8440679-B2 | Bicyclic compounds and their uses as dual c-SRC / JAK inhibitors | DEBIOPHARM S.A. (CH) | 2013-05-14 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| WO-2011101806-A1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | DEBIOPHARM S.A. (CH) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | SMN1; SMN2 4581/4885NPC1 1892/4885RAB9A 3030/4885 |
| US-11802128-B2 | Azetidine and pyrrolidine PARP1 inhibitors and uses thereof | PARP1, PARP11, PARP12 | SMN1; SMN2 3578/4885NPC1 2929/4885RAB9A 1110/4885 |
| US-20230203033-A1 | AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP12 | SMN1; SMN2 3533/4885NPC1 3172/4885RAB9A 1205/4885 |
| US-20230128041-A1 | PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP12 | SMN1; SMN2 3751/4885NPC1 2940/4885RAB9A 3330/4885 |
| US-20180111937-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TNF | TNF, TNFRSF1A, TNFRSF9 | SMN1; SMN2 4361/4885NPC1 3950/4885RAB9A 1442/4885 |
| US-20140011800-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | JAK3, JAK1, JAK2 | SMN1; SMN2 4827/4885NPC1 4824/4885RAB9A 2466/4885 |
| US-10308652-B2 | Tricyclic heterocyclic compounds useful as inhibitors of TNF | TNF, TNFRSF1A, TNFRSF9 | SMN1; SMN2 4361/4885NPC1 3950/4885RAB9A 1442/4885 |
| US-11591331-B2 | PARP1 inhibitors and uses thereof | PARP1, PARP11, PARP12 | SMN1; SMN2 3751/4885NPC1 2940/4885RAB9A 3330/4885 |
| US-20130143895-A1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | JAK2, SRC, JAK1 | SMN1; SMN2 4607/4885NPC1 3689/4885RAB9A 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.